vimarsana.com
Home
Live Updates
Atossa Therapeutics Presents Data from 40mg Cohort of Phase : vimarsana.com
Atossa Therapeutics Presents Data from 40mg Cohort of Phase
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and...
Related Keywords
United States ,
American ,
Eric Van Zanten ,
Nusaybaa Bagegni ,
American Association For Cancer Research ,
Nasdaq ,
Division Of Oncology ,
Company Phase ,
Washington University School Of Medicine ,
Atossa Therapeutics Inc ,
Endoxifen Versus ,
Human Epidermal Growth Factor Receptor ,
American Association ,
Cancer Research ,
Annual Meeting ,
Response Evaluation Criteria In Solid Tumors ,
Associate Professor ,
Washington University School ,
Steven Quay ,
Chief Executive ,
Selective Estrogen Receptor Modulator ,
Premenopausal Patients ,
Nasdaq Atos ,
Atossa Therapeutics ,
Nc ,
vimarsana.com © 2020. All Rights Reserved.